Bristol-Myers Squibb Co., of New York, the California Institute for Biomedical Research (Calibr) entered into a worldwide research collaboration to develop small-molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr's preclinical compounds resulting from the collaboration.